ERBB2 and cancer: This may be attributed to the fact that, while pertuzumab and trastuzumab bind distinct ECD of HER2 and effectively inhibit dimerization, they do not completely prevent all forms of HER2 dimerization [36], particularly those pre-existing in cancer cells.